| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.887 | 0.004 | 0.887 | Aldehyde oxidase inhibitor | 0.749 0.005 DBMET01670 | ||
| 0.784 | 0.013 | 0.784 | Caspase 9 stimulant | 0.456 0.08 DBMET01670 | ||
| 0.564 | 0.009 | 0.597 | Anticonvulsant | 0.597 0.007 DBMET01670 | DBMET01670 | |
| 0.558 | 0.015 | 0.558 | Histamine release inhibitor | 0.454 0.048 DBMET01670 | ||
| 0.484 | 0.004 | 0.484 | Nav1.3 sodium channel blocker | 0.235 0.016 DBMET01670 | ||
| 0.483 | 0.025 | 0.483 | Spasmolytic | 0.302 0.069 DBMET01670 | ||
| 0.437 | 0.007 | 0.437 | 5 Hydroxytryptamine 2B antagonist | 0.183 0.03 DBMET01670 | ||
| 0.437 | 0.012 | 0.437 | Cyclic AMP phosphodiesterase inhibitor | 0.218 0.081 DBMET01670 | ||
| 0.429 | 0.006 | 0.429 | Nav1.2 sodium channel blocker | 0.199 0.035 DBMET01670 | ||
| 0.41 | 0.004 | 0.41 | Nav1.6 sodium channel blocker | 0.205 0.018 DBMET01670 | ||
| 0.397 | 0.005 | 0.397 | 5 Hydroxytryptamine 2C antagonist | 0.151 0.026 DBMET01670 | ||
| 0.381 | 0.011 | 0.381 | 5 Hydroxytryptamine 2 antagonist | 0.148 0.045 DBMET01670 | ||
| 0.385 | 0.04 | 0.385 | Vasodilator, coronary | 0.258 0.126 DBMET01670 | ||
| 0.332 | 0.005 | 0.419 | Histamine H1 receptor antagonist | 0.419 0.004 DBMET01670 | DBMET01670 | |
| 0.323 | 0.01 | 0.323 | 5 Hydroxytryptamine 2A antagonist | 0.112 0.041 DBMET01670 | ||
| 0.314 | 0.011 | 0.314 | Dopamine antagonist | 0.28 0.013 DBMET01670 | ||
| 0.309 | 0.013 | 0.416 | Antipruritic | 0.416 0.006 DBMET01670 | DBMET01670 | |
| 0.302 | 0.013 | 0.302 | Adenylate cyclase inhibitor | 0.152 0.044 DBMET01670 | ||
| 0.294 | 0.01 | 0.294 | Calcium channel blocker | 0.275 0.013 DBMET01670 | ||
| 0.312 | 0.046 | 0.312 | HERG channel blocker | 0.266 0.06 DBMET01670 | ||
| 0.288 | 0.022 | 0.288 | Neurotrophic factor enhancer | 0.224 0.055 DBMET01670 | ||
| 0.273 | 0.01 | 0.273 | Nav1.1 sodium channel blocker | 0.17 0.026 DBMET01670 | ||
| 0.262 | 0.012 | 0.262 | Dopamine D2 antagonist | 0.261 0.012 DBMET01670 | ||
| 0.314 | 0.079 | 0.314 | Calcium channel activator | 0.291 0.1 DBMET01670 | ||
| 0.243 | 0.008 | 0.243 | Dopamine D1 antagonist | 0.079 0.033 DBMET01670 | ||
| 0.236 | 0.002 | 0.236 | Ca2+-transporting ATPase inhibitor | 0.197 0.004 DBMET01670 | ||
| 0.23 | 0.009 | 0.23 | Dopamine D3 antagonist | 0.097 0.026 DBMET01670 | ||
| 0.242 | 0.022 | 0.242 | Anesthetic local | |||
| 0.299 | 0.079 | 0.299 | Caspase 3 stimulant | |||
| 0.336 | 0.116 | 0.336 | Analgesic | |||
| 0.275 | 0.058 | 0.275 | Potassium channel (Voltage-sensitive) blocker | 0.231 0.077 DBMET01670 | ||
| 0.232 | 0.016 | 0.302 | Antihistaminic | 0.302 0.01 DBMET01670 | DBMET01670 | |
| 0.22 | 0.006 | 0.22 | Sphingomyelinase inhibitor | 0.122 0.04 DBMET01670 | ||
| 0.22 | 0.009 | 0.22 | MAP3K9 inhibitor | 0.2 0.015 DBMET01670 | ||
| 0.225 | 0.02 | 0.225 | Antiadrenergic | 0.106 0.053 DBMET01670 | ||
| 0.23 | 0.028 | 0.23 | 5 Hydroxytryptamine antagonist | |||
| 0.219 | 0.02 | 0.219 | Adrenaline antagonist | 0.102 0.053 DBMET01670 | ||
| 0.23 | 0.031 | 0.23 | Acetylcholine M1 receptor antagonist | 0.141 0.083 DBMET01670 | ||
| 0.215 | 0.017 | 0.255 | Histamine antagonist | 0.255 0.013 DBMET01670 | DBMET01670 | |
| 0.22 | 0.024 | 0.22 | Alpha adrenoreceptor antagonist | |||
| 0.196 | 0.015 | 0.196 | Alpha 1b adrenoreceptor antagonist | 0.073 0.051 DBMET01670 | ||
| 0.196 | 0.015 | 0.387 | Mediator release inhibitor | 0.387 0.005 DBMET01670 | DBMET01670 | |
| 0.235 | 0.057 | 0.235 | Ca2+/calmodulin-dependent kinase II beta inhibitor | |||
| 0.189 | 0.014 | 0.189 | 5 Hydroxytryptamine 7 antagonist | 0.079 0.032 DBMET01670 | ||
| 0.303 | 0.132 | 0.303 | MAP kinase kinase 6 inhibitor | |||
| 0.192 | 0.022 | 0.192 | Alpha 1 adrenoreceptor antagonist | |||
| 0.175 | 0.007 | 0.175 | Calcium channel L-type blocker | 0.122 0.015 DBMET01670 | ||
| 0.275 | 0.108 | 0.275 | Cholesterol antagonist | |||
| 0.208 | 0.044 | 0.208 | Cytidine deaminase inhibitor | 0.118 0.102 DBMET01670 | ||
| 0.26 | 0.098 | 0.26 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.332 | 0.172 | 0.332 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.277 0.246 DBMET01670 | ||
| 0.171 | 0.012 | 0.171 | Alpha 1d adrenoreceptor antagonist | 0.058 0.042 DBMET01670 | ||
| 0.215 | 0.059 | 0.215 | Insulin sensitizer | |||
| 0.172 | 0.024 | 0.172 | Calcium channel (voltage-sensitive) blocker | 0.138 0.041 DBMET01670 | ||
| 0.152 | 0.006 | 0.152 | Dopamine D5 antagonist | 0.073 0.014 DBMET01670 | ||
| 0.175 | 0.03 | 0.175 | Alpha 2b adrenoreceptor antagonist | |||
| 0.166 | 0.024 | 0.166 | Protein kinase C gamma inhibitor | 0.123 0.05 DBMET01670 | ||
| 0.187 | 0.049 | 0.187 | ATPase inhibitor | 0.135 0.13 DBMET01670 | ||
| 0.17 | 0.034 | 0.198 | Sphingosine 1-phosphate receptor 5 antagonist | 0.198 0.012 DBMET01670 | DBMET01670 | |
| 0.158 | 0.022 | 0.158 | Alpha 1a adrenoreceptor antagonist | |||
| 0.149 | 0.02 | 0.149 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.124 | 0.003 | 0.124 | Adenylate cyclase 1 inhibitor | 0.08 0.008 DBMET01670 | ||
| 0.138 | 0.019 | 0.138 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.19 | 0.071 | 0.201 | P-glycoprotein inhibitor | 0.201 0.063 DBMET01670 | DBMET01670 | |
| 0.15 | 0.032 | 0.15 | Alpha 2c adrenoreceptor antagonist | |||
| 0.126 | 0.009 | 0.126 | CC chemokine 2 receptor antagonist | 0.094 0.015 DBMET01670 | ||
| 0.219 | 0.103 | 0.25 | Cardiotonic | 0.25 0.082 DBMET01670 | DBMET01670 | |
| 0.161 | 0.049 | 0.225 | Toll-Like receptor antagonist | 0.225 0.022 DBMET01670 | DBMET01670 | |
| 0.136 | 0.026 | 0.136 | Alcohol dehydrogenase inhibitor | 0.115 0.038 DBMET01670 | ||
| 0.141 | 0.031 | 0.141 | Sphingosine 1-phosphate receptor 2 agonist | 0.102 0.096 DBMET01670 | ||
| 0.116 | 0.008 | 0.116 | Protein kinase C beta inhibitor | 0.08 0.031 DBMET01670 | ||
| 0.147 | 0.039 | 0.147 | Calcium channel N-type blocker | 0.137 0.046 DBMET01670 | ||
| 0.133 | 0.027 | 0.133 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.123 | 0.021 | 0.123 | Dopamine D4 antagonist | |||
| 0.202 | 0.101 | 0.202 | MAP-kinase-activated kinase 5 inhibitor | |||
| 0.187 | 0.087 | 0.187 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.146 | 0.046 | 0.146 | Acetylcholine muscarinic antagonist | 0.102 0.088 DBMET01670 | ||
| 0.148 | 0.049 | 0.148 | Heat shock protein 70 antagonist | |||
| 0.127 | 0.028 | 0.127 | Protein kinase C zeta inhibitor | 0.092 0.062 DBMET01670 | ||
| 0.118 | 0.022 | 0.118 | Histamine H2 receptor antagonist | 0.08 0.066 DBMET01670 | ||
| 0.121 | 0.03 | 0.121 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.134 | 0.043 | 0.134 | Photosensitizer | |||
| 0.202 | 0.115 | 0.202 | Superoxide dismutase inhibitor | |||
| 0.211 | 0.136 | 0.211 | Ca2+/calmodulin-dependent kinase IV inhibitor | |||
| 0.079 | 0.005 | 0.079 | GABA uptake inhibitor | 0.079 0.005 DBMET01670 | ||
| 0.099 | 0.026 | 0.099 | 5 Hydroxytryptamine uptake inhibitor | 0.056 0.05 DBMET01670 | ||
| 0.136 | 0.066 | 0.136 | NADPH oxidase inhibitor | |||
| 0.095 | 0.025 | 0.095 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.105 | 0.036 | 0.105 | Glutamate release inhibitor | |||
| 0.109 | 0.042 | 0.109 | Calcium antagonist | |||
| 0.11 | 0.043 | 0.11 | Ca(v)2.2 blocker | |||
| 0.122 | 0.055 | 0.141 | GABA receptor agonist | 0.141 0.041 DBMET01670 | DBMET01670 | |
| 0.176 | 0.11 | 0.214 | Potassium channel blocker | 0.214 0.084 DBMET01670 | DBMET01670 | |
| 0.106 | 0.041 | 0.106 | Histamine N-methyltransferase inhibitor | |||
| 0.113 | 0.051 | 0.113 | Butyrylcholinesterase inhibitor | |||
| 0.085 | 0.024 | 0.085 | Potassium channel (Tandem pore domain) blocker | |||
| 0.084 | 0.024 | 0.084 | Dopamine uptake inhibitor | |||
| 0.094 | 0.034 | 0.094 | Interferon agonist | 0.078 0.055 DBMET01670 | ||
| 0.109 | 0.05 | 0.109 | Creatine kinase inhibitor | 0.096 0.064 DBMET01670 | ||
| 0.118 | 0.059 | 0.118 | Estrogen antagonist | |||
| 0.081 | 0.023 | 0.081 | Interferon inducer | 0.068 0.038 DBMET01670 | ||
| 0.216 | 0.158 | 0.23 | Vasodilator, peripheral | 0.23 0.144 DBMET01670 | DBMET01670 | |
| 0.133 | 0.075 | 0.193 | Toll-Like receptor 9 antagonist | 0.193 0.039 DBMET01670 | DBMET01670 | |
| 0.108 | 0.052 | 0.108 | Insulin receptor antagonist | |||
| 0.076 | 0.021 | 0.076 | Potassium channel intermediate-conductance Ca-activated blocker | 0.055 0.054 DBMET01670 | ||
| 0.094 | 0.039 | 0.094 | Alpha 2a adrenoreceptor antagonist | |||
| 0.223 | 0.169 | 0.223 | Calpain 2 inhibitor | |||
| 0.082 | 0.033 | 0.082 | Acetylcholine M5 receptor agonist | |||
| 0.143 | 0.094 | 0.143 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | |||
| 0.121 | 0.072 | 0.121 | Cholinergic antagonist | |||
| 0.068 | 0.021 | 0.068 | Myc inhibitor | |||
| 0.17 | 0.123 | 0.17 | Antiamyloidogenic | |||
| 0.135 | 0.09 | 0.135 | NOS3 expression enhancer | |||
| 0.084 | 0.042 | 0.084 | Acetylcholine M4 receptor antagonist | |||
| 0.084 | 0.042 | 0.13 | Telomerase inhibitor | 0.13 0.024 DBMET01670 | DBMET01670 | |
| 0.084 | 0.043 | 0.084 | Estrogen receptor alpha antagonist | |||
| 0.077 | 0.037 | 0.102 | Cannabinoid receptor agonist | 0.102 0.025 DBMET01670 | DBMET01670 | |
| 0.101 | 0.062 | 0.101 | Estrogen receptor beta antagonist | |||
| 0.145 | 0.107 | 0.145 | Amyloid beta precursor protein antagonist | |||
| 0.068 | 0.03 | 0.068 | Protein kinase C eta inhibitor | |||
| 0.088 | 0.05 | 0.097 | GABA A receptor agonist | 0.097 0.041 DBMET01670 | DBMET01670 | |
| 0.069 | 0.032 | 0.069 | Acetylcholine M5 receptor antagonist | |||
| 0.088 | 0.051 | 0.088 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | |||
| 0.096 | 0.06 | 0.096 | Phosphodiesterase 6D inhibitor | 0.093 0.068 DBMET01670 | ||
| 0.066 | 0.031 | 0.066 | Cannabinoid CB2 receptor agonist | |||
| 0.205 | 0.172 | 0.205 | Apoptosis antagonist | |||
| 0.117 | 0.086 | 0.117 | Ca2+/calmodulin-dependent kinase II delta inhibitor | |||
| 0.068 | 0.037 | 0.068 | 5 Hydroxytryptamine 3 agonist | |||
| 0.2 | 0.169 | 0.2 | Transcription factor NF kappa B inhibitor | |||
| 0.159 | 0.128 | 0.159 | Hypolipemic | |||
| 0.11 | 0.079 | 0.11 | Transcription factor STAT6 inhibitor | |||
| 0.044 | 0.013 | 0.044 | ATM kinase inhibitor | |||
| 0.066 | 0.036 | 0.066 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.059 | 0.029 | 0.059 | Sigma receptor antagonist | |||
| 0.11 | 0.08 | 0.11 | Acetylcholine antagonist | |||
| 0.129 | 0.104 | 0.129 | Sigma receptor agonist | |||
| 0.034 | 0.009 | 0.034 | Estrogen-related receptor gamma antagonist | 0.031 0.014 DBMET01670 | ||
| 0.074 | 0.05 | 0.074 | Lipase inhibitor | |||
| 0.046 | 0.023 | 0.046 | Nerve growth factor antagonist | |||
| 0.167 | 0.145 | 0.167 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.067 | 0.048 | 0.067 | MDM2 inhibitor | |||
| 0.145 | 0.126 | 0.145 | MAP kinase kinase 2 inhibitor | |||
| 0.111 | 0.093 | 0.111 | DNA repair enzyme inhibitor | |||
| 0.203 | 0.185 | 0.203 | Ca(v)3.3 blocker | |||
| 0.058 | 0.04 | 0.058 | 5 Hydroxytryptamine 5 antagonist | |||
| 0.035 | 0.017 | 0.035 | Vanilloid 4 antagonist | |||
| 0.06 | 0.043 | 0.06 | Carbamoyl phosphate synthetase inhibitor | |||
| 0.095 | 0.078 | 0.095 | Beta glucuronidase inhibitor | |||
| 0.054 | 0.037 | 0.054 | Sphingosine 1-phosphate receptor 5 agonist | |||
| 0.051 | 0.036 | 0.051 | 5 Hydroxytryptamine 4 antagonist | |||
| 0.118 | 0.104 | 0.118 | Mannose-6-phosphate isomerase inhibitor | |||
| 0.028 | 0.015 | 0.028 | Thymidine kinase (Herpes simplex virus 1) inhibitor | |||
| 0.079 | 0.067 | 0.079 | Alpha 2 adrenoreceptor antagonist | |||
| 0.048 | 0.037 | 0.065 | Potassium channel (Inward rectifier) blocker | 0.065 0.02 DBMET01670 | DBMET01670 | |
| 0.086 | 0.076 | 0.086 | MAP kinase kinase 1 inhibitor | |||
| 0.035 | 0.026 | 0.035 | Ceramide glucosyltransferase inhibitor | |||
| 0.124 | 0.115 | 0.124 | Adenylate cyclase stimulant | |||
| 0.063 | 0.055 | 0.063 | Protein kinase C alpha inhibitor | |||
| 0.051 | 0.043 | 0.051 | Lysine-specific demethylase 1A inhibitor | |||
| 0.042 | 0.035 | 0.042 | 5 Hydroxytryptamine 1A agonist | |||
| 0.026 | 0.019 | 0.026 | Calcium-sensing receptor agonist | |||
| 0.235 | 0.229 | 0.235 | Cyclophilin D inhibitor | |||
| 0.104 | 0.098 | 0.104 | Toll-Like receptor 2 antagonist | |||
| 0.055 | 0.05 | 0.055 | Adrenaline uptake inhibitor | |||
| 0.054 | 0.049 | 0.091 | Cannabinoid CB1 receptor agonist | 0.091 0.023 DBMET01670 | DBMET01670 | |
| 0.052 | 0.047 | 0.052 | Alpha 1 adrenoreceptor agonist | |||
| 0.031 | 0.027 | 0.031 | Protein kinase C beta II inhibitor | |||
| 0.061 | 0.058 | 0.061 | Potassium channel large-conductance Ca-activated activator | |||
| 0.04 | 0.037 | 0.04 | Stearoyl-CoA desaturase inhibitor | |||
| 0.02 | 0.017 | 0.02 | Thymidine kinase (Herpes simplex virus 2) inhibitor | |||
| 0.036 | 0.033 | 0.036 | Dopamine D3 agonist | |||
| 0.087 | 0.084 | 0.087 | Nitric-oxide synthase inhibitor | |||
| 0.113 | 0.11 | 0.113 | Cell wall synthesis inhibitor | |||
| 0.058 | 0.056 | 0.058 | Sphingosine 1-phosphate receptor 4 agonist | |||
| 0.05 | 0.049 | 0.05 | 5 Hydroxytryptamine 6 antagonist | |||
| 0.037 | 0.036 | 0.037 | Thymidine kinase inhibitor | |||
| 0.059 | 0.058 | 0.059 | Beta 3 adrenoreceptor antagonist | |||
| 0.04 | 0.053 | 0.05 | Neurokinin antagonist | 0.05 0.034 DBMET01670 | DBMET01670 | |
| 0.153 | 0.178 | 0.163 | 5 Hydroxytryptamine release stimulant | 0.163 0.162 DBMET01670 | DBMET01670 | |
| 0.025 | 0.058 | 0.04 | Neurokinin 2 antagonist | 0.04 0.03 DBMET01670 | DBMET01670 | |
| 0.061 | 0.1 | 0.111 | NMDA receptor antagonist | 0.111 0.04 DBMET01670 | DBMET01670 | |
| 0.1 | 0.158 | 0.135 | Sphingosine 1-phosphate receptor 2 antagonist | 0.135 0.064 DBMET01670 | DBMET01670 | |
| 0.017 | 0.14 | 0.034 | Benzodiazepine receptor peripheral-type antagonist | 0.034 0.024 DBMET01670 | DBMET01670 | |
| 0.114 | 0.26 | 0.209 | Thyroid hormone beta antagonist | 0.209 0.147 DBMET01670 | DBMET01670 | |
| 0.007 | 0.172 | 0.026 | Carnitine palmitoyltransferase 1A inhibitor | 0.026 0.024 DBMET01670 | DBMET01670 | |
| 0.137 | 0.304 | 0.265 | Toll-Like receptor 7 agonist | 0.265 0.135 DBMET01670 | DBMET01670 | |
| 0.136 | 0.303 | 0.264 | Toll-Like receptor agonist | 0.264 0.136 DBMET01670 | DBMET01670 | |
| 0.106 | 0.275 | 0.205 | Thyroid hormone antagonist | 0.205 0.157 DBMET01670 | DBMET01670 | |
| 0.022 | 0.211 | 0.093 | Leukotriene synthesis inhibitor | 0.093 0.03 DBMET01670 | DBMET01670 | |
| 0.084 | 0.274 | 0.225 | Tumour necrosis factor alpha release inhibitor | 0.225 0.089 DBMET01670 | DBMET01670 | |
| 0.044 | 0.34 | 0.198 | Interleukin 1 antagonist | 0.198 0.034 DBMET01670 | DBMET01670 | |
| 0.029 | 0.473 | 0.18 | Interleukin 1b antagonist | 0.18 0.025 DBMET01670 | DBMET01670 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |